Table 5.
Baseline characteristics according to stent occlusion, n (%)
| Patent stent group (n = 41, 71.9%) | Stent occlusion group (n = 16, 28.1%) | P value | |
| Age (yr, mean ± SD) | 56.2 ± 12.4 | 58.3 ± 7.9 | 0.660 |
| Male | 15 (36.6) | 8 (50.0) | 0.354 |
| Primary malignancy | 0.231 | ||
| Upper abdominal cancer | 28 (68.3) | 14 (87.5) | |
| Lower abdominal cancer | 11 (26.8) | 1 (6.3) | |
| Extra abdominal cancer | 2 (4.9) | 1 (6.3) | |
| Obstruction site | 0.198 | ||
| Left colon | 28 (68.3) | 8 (50.0) | |
| Sigmoid colon | 13 (31.7) | 8 (50.0) | |
| Obstruction | 1.000 | ||
| Partial | 4 (9.8) | 2 (12.5) | |
| Near total | 37 (90.2) | 14 (87.5) | |
| Peritoneal carcinomatosis | 31 (75.6) | 11 (68.8) | 0.739 |
| Previous chemotherapy | 35 (85.4) | 14 (87.5) | 1.000 |
| Previous radiotherapy | 6 (14.6) | 3 (18.8) | 0.700 |
| Stent length ≤ 10 cm | 21 (51.2) | 15 (93.8) | 0.003 |
Upper abdominal cancer: Gastric cancer and pancreaticobiliary cancer; Lower abdominal cancer: Ovarian cancer, uterine cancer, and bladder cancer; Left colon: From the rectum to descending colon; Right colon: From the splenic flexure to ascending colon.